The ILLUMINATE-204 trial shows an overall response rate of 38% with 2 complete responses, suggesting a promising strategy for treating patients with metastatic melanoma unresponsive to PD-1 therapy. The combination regimen is generally well-tolerated, with fewer than a quarter of patients experiencing immune-related toxicities.
A new study shows that the innovative OnTouch Via patch enabled over 50% of diabetes patients to report improved insulin dose compliance. The wearable patch allows for discreet delivery of rapid-acting insulin at mealtimes, reducing stress and anxiety associated with dosing.
A global survey found that most adults (72%) believe they have a 'healthy' or 'optimal' diet, despite the high prevalence of diseases associated with dietary deficiencies. The survey also revealed that less than half of respondents consume enough Omega-3s and Vitamin D through food sources alone.
A study of 307 patients with treatment-resistant MDD found that NeuroStar TMS Therapy induced significant response and remission, which were maintained through 52 weeks. At one year, 68% achieved symptomatic improvement and 45% reported complete remission.
A clinical feasibility study demonstrated that the algorithm was capable of helping maintain glucose above hypoglycemic levels for an average of 99.1 percent of the time. The system's potential to reduce hypoglycemia via a technological approach was underscored by significant differences in insulin dosing response as the aggressiveness...
The clinical validation study showed ProMark correctly identified low-risk disease with a sensitivity of 90% or better. The test provided additional independent prediction relative to standard risk-stratification systems, improving personalized treatment decisions for prostate cancer patients.
The investigational vaccine generates an immune response against key toxins in volunteers and establishes a dosing regimen for Phase III trials, which could help prevent first-occurrence CDI and protect individuals from this potentially life-threatening infection.
A real-world study evaluating the benefit of treating asthma with small particle treatments like QVAR compared to larger particle treatments revealed interesting differences in asthma exacerbation outcome rates. The study found that initiating dosing with small versus large particle ICS treatments can impact asthma control rates.
A new analysis of data from two independent studies shows that Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than conventional antidepressant medication among patients with Major Depressive Disorder who failed to benefit from prior treatment. Additiona...
A pilot study revealed that once-monthly NeuroStar TMS maintenance therapy induced remission in 61.2% of medication-free patients with Major Depressive Disorder after 6 weeks. At three months, 62.5% of these patients maintained response compared to 43.8% without maintenance treatment.
Researchers found high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP) cholesterol levels are linked to CHD risk. HDL3 subfractions, not traditional HDL cholesterol, were more predictive in assessing and reducing CHD risk.
New findings show STELARA significantly inhibits structural damage progression at week 24 and maintains effect through two years. Treatment with STELARA results in reduced total psoriatic arthritis modified vdH-S scores compared to placebo.
The predictive Hypoglycemia-Hyperglycemia Minimizer (HHM) System demonstrated that it can maintain safe glucose levels overnight, with participants spending over 90% of the time within a target range. The system showed encouraging performance in controlling blood glucose values during the critical nighttime period.
A clinical study demonstrates the durability of NeuroStar TMS Therapy in patients with Major Depressive Disorder (MDD) who have failed to respond to prior antidepressant medication. After acute treatment, patients maintained significant improvement and remission through 12 months, suggesting a long-term benefit of the therapy.
The data presented at the AUA Annual Meeting shows that degarelix lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists. Analysis of disease control-related outcomes from six comparative randomised clinical trials also supports this finding.
A second-phase human clinical trial showed the predictive glucose control system can reduce insulin delivery in advance of hypoglycemia and trigger timely warnings. The system demonstrated promising results, keeping glucose levels at an average of 133 mg/dL for the entire cohort.